Publications by authors named "Panayota Bird"
Article Synopsis
- Tafenoquine, a single 300 mg dose combined with a 3-day chloroquine treatment, is approved for curing Plasmodium vivax malaria in patients 16 and older, offering a more convenient alternative to the traditional multi-day regimens with primaquine.
- * The World Health Organization (WHO) recommends longer primaquine treatments which can lead to poor adherence, whereas tafenoquine's single-dose approach enhances patient compliance.
- * Safety studies indicate that tafenoquine has a similar safety profile to primaquine, but both can cause serious complications in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, so G6PD testing is essential before treatment.*
A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of malaria in patients aged ≥16 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is insufficient for radical cure, and that a higher 450 mg dose could reduce P.
View Article and Find Full Text PDFIndia contributes to over 40% of the global Plasmodium vivax disease burden, and P. vivax contributes to approximately one-third of all malaria in India. Government of India has set goals to eliminate malaria by 2030.
View Article and Find Full Text PDF